Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph Papa dated as of January 3, 2022

Exhibit 10.18

ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT

This assignment, assumption and amendment agreement (the “Agreement”) is dated January 3, 2022 among Bausch Health Companies Inc., a corporation a corporation incorporated under the British Columbia Business Corporations Act (the “Assignor”), Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the “Assignee”) and Joseph C. Papa (the “Executive”) (the “Parties”, and each a “Party”).

RECITALS:

In consideration of the above and for other good and valuable consideration, including, the Executive’s employment in a new role with the Assignee, the Parties hereto agree as follows:

Section 1 Amendment of the Employment Agreement

The Parties hereto hereby agree that the Employment Agreement shall be amended as follows, effective as of the IPO Closing Date, subject to the closing of the IPO:

“For purposes of this Section 11(d), all references to the “Company and its affiliates” shall be deemed to include each of the Company, Bausch Health Companies Inc. (together with any successor thereto) (“BHC”), Solta Medical Corporation (together with any successor thereto) (“Solta”) and each of their respective subsidiaries and affiliates.”

“To protect the Confidential Information and other trade secrets of the Company and its affiliates, Executive agrees that during the Employment Term and for a period of twenty-four (24) months after Executive’s cessation of employment with the Company (the “Restricted Period”), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any Covered Employees (as defined below).”

“For purposes of this covenant, “Covered Employee” means (A) during the period ending on the date that is 12 months after the IPO Closing Date, (x) any employee of BHC, Solta, the Company or any of their respective subsidiaries or affiliates (including, for the avoidance of doubt, with respect to the Company’s global eye health business (the “B+L Business”) or the global aesthetics medical device business) or (y) any person who was an employee of BHC, Solta, the Company or any of their respective subsidiaries or affiliates during the six-month period preceding such action and (B) at any time following the end of the period described in clause (A), any employee of (x) the Company or any of its subsidiaries or affiliates or the B+L Business (including, for the avoidance of doubt, if employed by BHC or Solta or any of their subsidiaries or affiliates in the B+L Business) or (y) any person who was an employee of the Company or any of its subsidiaries or affiliates or the B+L Business (including by BHC or Solta), in each case during the six-month period preceding such action.”

“To protect the Confidential Information and other trade secrets of the Company and its affiliates, Executive agrees (i) during the period beginning on the date hereof and ending on the date that is 12 months after the IPO Closing Date, or the last day of the Restricted Period, if earlier (such period, the “First Period”), not to engage in Prohibited Activities (as defined below) in any country in which the Company, BHC, Solta or any of their affiliates conducts business, or plans to conduct business, and (ii) following the expiration of the First Period, during the Employment Term and the Restricted Period (the “Second Period”), Executive agrees not to engage in Prohibited Activities in any country in which the Company or any of its affiliates conducts business, or plans to conduct business. For the purposes of this Agreement, the term “Prohibited Activities” means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and/or distribution (directly or indirectly) of (x) during the First Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry (including, for the avoidance of

- 2 -

doubt, the global eye health business and the global aesthetics medical device business) and (y) during the Second Period, the global eye health business; provided that Prohibited Activities shall not mean (i) Executive’s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company’s outstanding voting securities or (ii) Executive serving as a member of a board of directors of a company provided that, for the avoidance of doubt, Executive complies with the obligations set forth in Sections 11 and 12(a) of this Agreement.

“Executive agrees and acknowledges that BHC shall at all times following the date hereof have the right to enforce, and be an express third-party beneficiary hereunder with respect to, Executive’s obligations under Section 11 and Section 12 of this Agreement and, accordingly, that BHC shall have all of the rights and remedies (including to the right to obtain injunctive relief against any breach or prospective breach of such obligations by Executive) as are afforded under this Agreement to the Company.”

Section 2 Assignment.

Effective as of and from the IPO Closing Date, subject to the occurrence of the closing of the IPO, the Assignor hereby assigns to the Assignee all of the Assignor’s rights, title and interest in and to, and all benefits of the Assignor under, the Employment Agreement. In the event the closing of the IPO does not occur for any reason, this Agreement will be null and void and of no force or effect and the Employment Agreement will continue in effect in accordance with its terms without giving effect to this Agreement.

Section 3 Assumption by Assignee.

Effective as of and from the IPO Closing Date, subject to the occurrence of the closing of the IPO, the Assignee hereby assumes and agrees to perform and discharge all the obligations and liabilities of the Assignor under the Employment Agreement, and accordingly the Parties agree that as and from the IPO Closing Date, the term the “Company” under the Employment Agreement shall refer to the Assignee except as otherwise set forth in this Agreement.

Section 4 Further Assurances.

On or after the date of this Agreement, each Party hereto shall execute and deliver such documents and take all such action as is reasonably required to carry out the intent and purpose of this Agreement. Except as specifically amended and supplemented hereby, the Employment Agreement shall remain in full force and effect in accordance with its terms.

Section 5 Successors and Assigns.

This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto, their successors and permitted assigns and the Parties shall require any successor or assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the applicable Party would be required to perform if no such succession or assignment had taken place. The Parties may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Party, as applicable.

- 3 -

Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by the Executive, the Executive’s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.

This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal personal representatives.

Section 6 No Third Party Beneficiaries.

The Parties hereto shall have the sole right to enforce the performance of the provisions of this Agreement. Except for the Parties hereto or as expressly contemplated by Section 1(e) of this Agreement, this Agreement is not intended for the benefit of, and is not intended to be relied upon by, any other person and no such person (or any other person acting on its behalf) shall be entitled to the benefit of or to enforce this Agreement.

Section 7 Amendment and Waiver.

No provision of this Agreement may be altered, amended and/or waived except by a written document signed by all Parties hereto setting forth such alteration, amendment, and/or waiver. The Parties hereto agree that the failure to enforce any provision or obligation under this Agreement shall not constitute a waiver thereof or serve as a bar to the subsequent enforcement of such provision or obligation or any other provisions or obligations under this Agreement. No course of dealing between or among any persons having any interest in this Agreement will be deemed effective to modify or amend any part of this Agreement or any rights or obligations of any person under or by reason of this Agreement.

Section 8 Severability.

The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.

Section 9 Governing Law.

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof.

Section 10 Counterparts.

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

[Signature page follows]

- 4 -

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first written above.

[Signature Page to Assignment, Assumption and Amendment Agreement – Employment Agreement]

- 5 -